A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study.

Suzanne Shusterman,Jacek Gan,Stephen Gillies,Paul M Sondel,John M Maris,Hiroyuki Shimada,Barry L Shulkin,Arlene Naranjo,Jacquelyn A Hank,Julie R Park,Sabah-E-Noor Servaes,Marguerite T Parisi,Wendy B London

doi:10.1200/jco.2015.33.15_suppl.10017

A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study.

Suzanne Shusterman, Jacek Gan + Show 11 more

https://doi.org/10.1200/jco.2015.33.15_suppl.10017

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2015
Citations: 7

Affiliation: Dana-Farber Cancer Institute, University of Wisconsin–Madison, scPharmaceuticals (United States), Children's Hospital of Philadelphia, Children's Hospital of Los Angeles, St. Jude Children's Research Hospital, Children's Oncology Group, Seattle Children's Hospital

#Isotretinoin In Patients #Minimal Residual Disease + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

10017 Background: Combining anti-GD2 (disialoganglioside) monoclonal antibody with GM-CSF, IL2 and isotretinoin is now standard of care for high-risk neuroblastoma (NB) minimal residual disease (MR...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.